// STATE LEGISLATION TRACKER

Connecticut HB 5485: AN ACT ESTABLISHING A CAPTIVE INSURANCE COMPANY TO ADMINISTER A BULK PURCHASE AND DISTRIBUTION OF GLUCAGON-LIKE PEPTIDE-

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: Connecticut
Bill: HB 5485
Session: 2026
Filed: 2025-01-17
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Connecticut HB5485 creates a working group to study supported decision-making agreements for adults who want help making financial, health, or other decisions while keeping their own authority. It does not regulate compounded peptides, off-label prescribing, telehealth, clinician scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No direct change to peptide access or prescribing
No new rules for compounding pharmacies or 503A/503B outsourcing
No change to NP, naturopathic, or telehealth prescribing scope
Health-care settings may be part of the study recommendations
A report is due by December 31, 2026

What to Watch For

Note Watch the working group report for any health-care consent or records recommendations.

Note Supported decision-making could affect how some patients involve helpers in care decisions.

Note No current peptide-specific compliance change appears from the title, subjects, and final act text.

Where the Bill Stands

The governor approved the bill on June 2, 2026, so it has been signed into law as Special Act 26-12.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws